èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Minerva Neurosciences, Inc. ã¯ãäžæ¢ç¥çµç³»çŸæ£ã®æ²»çè¬åè£ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®äž»ååè£è¬ã¯ãçµ±å倱調çã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšäžã®ååç©ã§ãããã«ããªãã³ãšãããŒãã³ãœã³ç
ããã®ä»ã®ç¥çµå€æ§çŸæ£ã®æ²»çè¬ã§ãããã¥ãŒã¬ã°ãªã³ 1b1 ã¿ã³ãã¯è³ªã®å¯æº¶æ§çµã¿æãåã§ãã MIN-301 ã§ããMinerva Neurosciences, Inc. ã¯ãã¢ãžã¢ãé€ãäžçäžã§ãã«ããªãã³ãéçºã販売ã茞å
¥ããã©ã€ã»ã³ã¹å¥çŽãäžè±ç°èŸºè£œè¬æ ªåŒäŒç€Ÿãšç· çµããŠããŸããå瀟ã¯ã以å㯠Cyrenaic Pharmaceuticals, Inc. ãšããŠç¥ãããŠããŸãããã2013 幎㫠Minerva Neurosciences, Inc. ã«ç€Ÿåã倿ŽããŸãããMinerva Neurosciences, Inc. 㯠2007 幎ã«èšç«ãããããµãã¥ãŒã»ããå·ãŠã©ã«ãµã ã«æ¬ç€Ÿã眮ããŠããŸãã